摘要
目的分析促红细胞生成素(erythropoietin,EPO)对胆道梗阻再通大鼠肝功能恢复的影响。方法选择94只健康雄性Wistar大鼠为研究对象,随机分为4组,A组为假手术组(n=25),B组为梗阻性黄疸模型组(n=25),C组为梗阻性黄疸模型+胆道再通+生理盐水干预组(n=22)、D组为梗阻性黄疸模型+胆道再通+EPO干预组(n=22)。C组、D组胆道再通术后持续给药,干预1周,实验后检测肝功能(直接胆红素、总胆红素、丙氨酸转氨酶)、炎性因子(白介素-6、肿瘤坏死因子-α、C-反应蛋白)、红细胞计数,对比3个模型组疗效,观察有无不良反应。结果干预1周后,D组疗效优于C组(P<0.05)。治疗前,B~D组肝功能指标差异无统计学意义(P>0.05);治疗前与干预1周后,B~D组肝功能指标组内对比差异有统计学意义(P<0.01);干预1周后,A组、C组、D组直接胆红素、总胆红素、丙氨酸转氨酶水平低于B组,D组低于C组,组间差异有统计学意义(P<0.01);干预1周后,A组谷草转氨酶水平低于B~D组,C组、D组低于B组,D组低于C组,组间差异有统计学意义(P<0.01)。治疗前,4组组间炎性因子水平差异无统计学意义(P>0.05);治疗前与干预1周后,B~D组组内炎性因子水平对比,差异有统计学意义(P<0.01);干预1周后,C组、D组白介素-6、肿瘤坏死因子-α、C-反应蛋白水平低于B组,D组低于C组,组间差异有统计学意义(P<0.01)。治疗前,4组红细胞计数差异无统计学意义(P>0.05);干预1周后,A~C组红细胞计数与治疗前对比差异无统计学意义(P>0.05);干预1周后,D组红细胞计数与治疗前相比差异有统计学意义(P<0.01);干预1周后,D组红细胞计数水平高于A~C组,差异有统计学意义(P<0.01)。结论促红细胞生成素可促进红细胞分泌,抑制炎性因子,帮助胆道梗阻再通大鼠肝功能的恢复。
Objective To analyze the effects of erythropoietin(EPO) on liver function recovery in rats with biliary obstruction and recanalization.Methods A total of 94 healthy male Wistar rats were randomly divided into 4 groups.Group A was sham operation group(n=25),group B was obstructive jaundice model group(n=25),group C was obstructive jaundice model+biliary recanalization+saline intervention group(n=22),and group D was obstructive jaundice model+biliary recanalization+EPO intervention group(n=22).Group C and group D received continuous drug intervention for one week after biliary recanalization.After the experiment,liver function(direct bilirubin,total bilirubin,alanine aminotransferase),inflammatory factors(interleukin-6,tumor necrosis factor-α、C-reactive protein) and red blood cell count were measured.The curative effects of the three model groups were compared,and the occurrence of adverse reactions were observed during the treatment.Results After one week of intervention,the curative effect of group D was better than that of group C(P<0.05).Before treatment,there was no significant difference in liver function among groups B~D(P>0.05).After one week of intervention,there were significant difference in liver function indexes in groups B~D compared with before treatment(P<0.01).After one week of intervention,the levels of direct bilirubin,total bilirubin and alanine aminotransferase in group A,group C and group D were lower than those in group B,and group D were lower than those in group C(P<0.01).After one week of intervention,the level of glutamic oxaloacetic transaminase in group A was lower than that in group B~D,group C and group D were lower than that in group B,and group D was lower than that in group C,with statistical significance(P<0.01).Before treatment,there was no significant difference in the level of inflammatory factors among the four groups(P>0.05).There was significant difference in the levels of inflammatory factors in groups B~D before and after one week intervention(P<0.01).One week after intervention,interleukin-6 and tumor necrosis factor-α and C-reactive protein in group C and group D were lower than those in group B,and those in group D were lower than those in group C,with statistically significant difference(P<0.01).Before treatment,there was no significant difference in red blood cell count among the four groups(P>0.05).After one week of intervention,there was no significant difference in red blood cell count in group A~C compared with before treatment(P > 0.05).After one week of intervention,red blood cell count in group D was significant difference from that before treatment(P<0.01).One week after intervention,the red blood cell count in group D was significantly higher than that in groups A~C(P<0.01).Conclusion Erythropoietin can promote the secretion of erythrocytes and inhibit inflammatory factors to restore the liver function of rats with obstruction of biliary tract.
作者
肖洪斌
欧少君
李成碧
罗娟
王骏
XIAO Hongbin;OU Shaojun;LI Chengbi;LUO Juan;WANG Jun(Department of Gastroenterology,Tongchuan Red Cross Hospital,Dazhou 635000,Sichuan Province,China;Zunyi Medical College,Zunyi 563000,Guizhou Province,China)
出处
《世界临床药物》
2021年第9期766-771,共6页
World Clinical Drug
关键词
促红细胞生成素
胆道梗阻再通大鼠
肝功能
炎性因子
erythropoietin
rats with obstruction of biliary tract
liver function
inflammatory factor